Prospective Study In Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis B

Peking University First Hospital818 enrolled

Overview

The aim of our study is to evaluate liver fibrosis using biochemical markers, FibroScan, and radiology methods in patients with chronic hepatitis B in mainland China.

Up to Nov, 2015, total of 818 patients with chronic HBV infection had been enrolled in the study. Paired blood and liver biopsy specimen had been collected. The serum samples stored at -80 degree Celsius. All the liver biopsy samples were judged by three pathology experts, according to Ishak standard.

Study Type

OBSERVATIONAL

Enrollment

818

Conditions

Chronic Hepatitis B

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * clinical diagnosis of chronic hepatitis B or compensated cirrhosis due to chronic hepatitis B virus infection * agree to have liver biopsy Exclusion Criteria: * clinical diagnosis of decompensated cirrhosis due to hepatitis B virus or inactive carrier * liver diseases due to other origin

Locations (1)

Peking University First Hospital

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

Evaluation of staging fibrosis with a combination of non-invasive parameters compared to liver biopsy

Time frame: within two weeks after liver biopsy

Secondary Outcomes

Evaluation of staging inflammation with a combination of non-invasive parameters compared to liver biopsy

Time frame: within two weeks after liver biopsy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.